• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Retrovirus-mediated TCR Gene Transfer Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs develops various popular strategies to transfer TCR genes into T cells, one of which is mediated via retrovirus. With its high infection efficiency, stable recombinant gene expression ability and low immunogenicity, retroviruses have become the first choice in gene therapy researches, including some FDA-approved clinic trials. Our retrovirus-mediated TCR gene transfer solution consists of the construction of plasmid containing TCR gene, the generation of recombinant retroviruses and the production of virus particles with packing cells and the transduction TCR gene into T cells. Retroviruses infect target cells by binding of the viral envelope protein to cell surface receptors.

Figure: Retroviral gene transfer to generate tumor-specific T cells

Retroviruses can be found in almost all animals including chickens, mice, goats, primate, humans and fish. In clinical gene therapy, retroviral vectors are one of the most preferred transfer systems. Up to date, vectors derived from gamma-retroviruses such as murine leukemia viruses (MLVs) have been widely used for gene transfer into human T cells. Retroviral viral DNA can be stably incorporated into host genome and propagated in daughter cells, so retroviral vectors are appropriate tools to perform long-term expression of the transgene, achieving therapeutic efficacy. After entering host cells, the single-stranded RNA genome of retroviruses is released into the cytoplasm and converted into a double-stranded DNA by virus-encoded reverse transcriptase. Followed by which, the viral DNA forms pre-integration complex, a large nucleoprotein structure containing proteins which are important for nuclear localization and facilitate to insert viral DNA into the host genome. One of the most important barriers during the use of retrovirus vectors is they are unable to transduce nonproliferating target cells, while in many gene therapy protocols, target cells such as T cells are quiescent and induction of cell proliferation is to be avoided. Now, improved retroviral systems including retrovirus packing cells and vector components have been researched and developed to express cloning and functional genomics.

The most popular strategies used for TCR gene transfer:

References:

1. Youngsuk Yi, et al. Current Advances in Retroviral Gene Therapy. Curr Gene Ther. 2011 Jun; 11(3):218-28.
2. Toshio Kitamura, et al. Retrovirus-mediated gene transfer and expression cloning: Powerful tools in functional genomics. Exp Hematol. 2003 Nov;31(11):1007-14.
3. Els Verhoeyen, et al. Lentiviral Vector Gene Transfer into Human T Cells. Christopher Baum (ed.), Methods in Molecular Biology, Methods and Protocols, vol. 506.

To discuss your demands or to request a proposal, please contact us by .